J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.